Trials

Peking University Third Hospital, a top-tier (Grade 3A) general hospital in Beijing whose neurosurgery department is one of its key specialties, is taking part in a clinical trial of a Chinese-developed invasive brain-computer interface (BCI), neurosurgeons Yang Jun and Yu Tao wrote in the 16th issue of China Hospital CEO magazine. The trial enrolls patients with spinal cord injury and relies on a multidisciplinary team (MDT) to restore hand function after implantation. Invasive BCIs read neural signals through electrodes placed inside the skull or on the cortical surface, so surgery and rehabilitation depend on close coordination among neurosurgery, rehabilitation and imaging departments. The disclosure marks one step in Chinese hospitals' clinical validation of domestic systems. Public information has not named the system or disclosed enrollment, follow-up milestones or primary endpoints, and no efficacy or safety data have been released.

Zhejiang Provincial People's Hospital performed China's first 320-resolution visual BCI implant; a woman blind for nearly 20 years reportedly reads, writes and walks again.

Surgeons in eastern China have implanted a brain-computer interface in a man who has been unable to move his limbs for more than two years. Eight ultraflexible electrodes sit 4 mm into his cortex, wired to a chip mounted on the skull. It is the first invasive BCI operation performed in Shandong province, and the patient now begins up to six months of training to control devices by thought.

In Xiangya Hospital's invasive IMIE smart retina trial, a 61-year-old fully blind patient reportedly reached 0.03 stable and 0.1 best visual acuity, walking indoors unaided.

Onward Medical said the first participant in its global Empower BP pivotal study was enrolled and implanted with the investigational ARC-IM system at Craig Hospital in Denver during the first quarter of 2026. The randomized, double-blind, sham-controlled trial is evaluating management of blood-pressure instability after spinal cord injury across about 20 planned centers. Empower BP is not an upper-limb BCI trial, and the first implant did not take place in the Netherlands.